.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Julphar
Harvard Business School
Chinese Patent Office
Medtronic
Express Scripts
Cipla
AstraZeneca
Mallinckrodt
Teva
Covington

Generated: December 13, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020549

« Back to Dashboard

NDA 020549 describes FLOVENT, which is a drug marketed by Glaxosmithkline and Glaxo Grp Ltd and is included in four NDAs. There are sixteen patents protecting this drug. Additional details are available on the FLOVENT profile page.

The generic ingredient in FLOVENT is fluticasone propionate. There are twenty-five drug master file entries for this compound. Eighty-one suppliers are listed for this compound. Additional details are available on the fluticasone propionate profile page.

Summary for 020549

Tradename:1
Applicant:1
Ingredient:1
Patents:0
Therapeutic Class:Hormonal Agents, Stimulant/Replacement/Modifying (Adrenal)
Respiratory Tract Agents
Formulation / Manufacturing:see details

Summary for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:POWDER;INHALATIONStrength0.044MG/INH
Approval Date:Nov 7, 1997TE:RLD:No

Summary for product number 002

Active Rx/OTC/Discontinued:DISCNDosage:POWDER;INHALATIONStrength0.088MG/INH
Approval Date:Nov 7, 1997TE:RLD:No

Summary for product number 003

Active Rx/OTC/Discontinued:DISCNDosage:POWDER;INHALATIONStrength0.22MG/INH
Approval Date:Nov 7, 1997TE:RLD:No

Expired Orange Book Patents for NDA: 020549

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
GlaxosmithklineFLOVENTfluticasone propionatePOWDER;INHALATION020549-001Nov 7, 1997► Subscribe► Subscribe
GlaxosmithklineFLOVENTfluticasone propionatePOWDER;INHALATION020549-003Nov 7, 1997► Subscribe► Subscribe
GlaxosmithklineFLOVENTfluticasone propionatePOWDER;INHALATION020549-002Nov 7, 1997► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.



Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Baxter
Julphar
Argus Health
McKesson
Johnson and Johnson
Covington
Cantor Fitzgerald
Express Scripts
McKinsey
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot